A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies

Wei Jan Huang, Yen An Tang, Mei Yu Chen, Ying Jan Wang, Fu Han Hu, Tseng Wei Wang, Shi Wei Chao, Hui Wen Chiu, Ya Ling Yeh, Hsin Yi Chang, Hsueh Fen Juan, Pinpin Lin, Yi Ching Wang

研究成果: Article

18 引文 斯高帕斯(Scopus)

摘要

Many histone deacetylase (HDAC) inhibitors show limited therapeutic effects for solid tumors. Here, we develop a novel HDAC inhibitor YCW1 and verify the combination effect of YCW1 and cisplatin in lung cancer pre-clinical models. YCW1 exerted cancer-specific cytotoxicity via mitochondria-mediated apoptosis. YCW1 and cisplatin showed synergistic anti-tumor effects through impairment of DNA damage repair. YCW1 inhibited tumor growth in lung orthotopic and subcutaneously implanted xenograft models. YCW1 significantly suppressed lung metastases via inhibition of focal adhesion complex. Our findings suggested that YCW1 is a potential HDAC inhibitor for lung cancer treatment as single and in combination regimens with cisplatin.

原文English
頁(從 - 到)84-93
頁數10
期刊Cancer Letters
346
發行號1
DOIs
出版狀態Published - 2014 四月 28

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

指紋 深入研究「A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies」主題。共同形成了獨特的指紋。

  • 引用此